

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY .....	1
SCOPE OF REPORT .....	2
INTENDED AUDIENCE.....	3
METHODOLOGY AND INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	4
RELATED REPORTS.....	4
BCC ONLINE SERVICES.....	4
DISCLAIMER .....	5
 CHAPTER TWO: SUMMARY.....	 6
<i>SUMMARY TABLE GLOBAL EMERGING TECHNOLOGIES</i>	
<i>FORECAST BY AREA, THROUGH 2015 (\$ MILLIONS)</i> .....	6
<i>SUMMARY FIGURE GLOBAL EMERGING TECHNOLOGIES</i>	
<i>FORECAST BY AREA, 2009-2015 (\$ MILLIONS)</i> .....	7
SUMMARY (CONTINUED) .....	8
 CHAPTER THREE: THERAPEUTIC VACCINES .....	 9
OVERVIEW .....	9
<i>TABLE 1 GLOBAL MARKET FOR THERAPEUTIC VACCINES,</i>	
<i>THROUGH 2010 (\$ MILLIONS)</i> .....	9
KEY EVENTS IN THE THERAPEUTIC VACCINE MARKET.....	10
EXPANDING SEGMENT: PROPHYLACTIC CANCER	
VACCINES.....	10
VACCINE OPPORTUNITY SLACKENING DUE TO	
OVERCAPACITY.....	10
CELL CULTURE AND ADJUVANT TECHNOLOGY	
ENABLE THERAPEUTIC VACCINES .....	11
<i>TABLE 2 MARKET FORECAST FOR THERAPEUTIC VACCINES,</i>	
<i>THROUGH 2015 (\$ MILLIONS)</i> .....	11
LEADING VACCINE BRANDS.....	12
<i>TABLE 3 LEADING VACCINE BRANDS, THROUGH 2010 (\$</i>	
<i>MILLIONS)</i> .....	12
HEPATITIS VACCINES .....	12
PRODUCTS SUMMARY .....	12
<i>TABLE 4 MARKET FOR LEADING VACCINES: HEPATITIS</i>	
<i>SEGMENT, THROUGH 2010 (\$ MILLIONS)</i> .....	13
MARKET DYNAMICS.....	13
INFLUENZA VACCINES.....	14
<i>TABLE 5 MARKET FOR LEADING VACCINES: INFLUENZA</i>	
<i>SEGMENT, THROUGH 2010 (\$ MILLIONS)</i> .....	14
H1N1 SWINE FLU.....	15
MARKET DYNAMICS.....	15

PNEUMONIA VACCINES.....	16
MARKET DYNAMICS.....	16
MENINGITIS VACCINES.....	17
<i>TABLE 6 MARKET FOR LEADING VACCINES: MENINGITIS</i>	
<i>SEGMENT, THROUGH 2010 (\$ MILLIONS)</i> .....	17
MARKET DYNAMICS.....	18
OTHER VACCINES.....	18
HUMAN PAPILLOMAVIRUS (HPV) VACCINES.....	18
MARKET DYNAMICS.....	18
Market Dynamics (Continued).....	19
EMERGING TARGETS IN THERAPEUTIC VACCINES.....	20
THE NEW VACCINE STRATEGY: THERAPEUTIC	
VACCINES.....	20
Therapeutic Vaccines with Traditional Strategies.....	20
Antigen/Whole Cell Vaccines.....	20
Therapeutic Vaccines with Novel and Advanced	
Strategies.....	20
Dendritic Cell Vaccines.....	20
Cytolytic Viral Vaccines.....	21
DNA Vaccines.....	21
AFFiTOPE/AFFiTOME.....	22
Beta Amyloid.....	22
Somatostatin GHRH.....	23
Plasmid Encoders.....	24
Telomerase Endogenous Reverse Transcriptase (TERT).....	25
PIPELINE ANALYSIS.....	26
INTRODUCTION.....	26
RECENTLY APPROVED PRODUCTS.....	26
Menveo.....	26
<i>TABLE 7 PRODUCT PROFILE SUMMARY: MENVEO</i> .....	26
Menveo (Continued).....	27
Prevnar 13vPnC.....	28
<i>TABLE 8 PRODUCT PROFILE SUMMARY: PREVNAV 13VPNC</i> .....	28
Prevnar 13vPnC (Continued).....	29
Cervarix.....	30
<i>TABLE 9 PRODUCT PROFILE SUMMARY: CERVARIX</i> .....	30
Synflorix.....	31
<i>TABLE 10 PRODUCT PROFILE SUMMARY: SYNFLORIX</i> .....	31
Synflorix (Continued).....	32
Ixiaro/Jespect.....	33
<i>TABLE 11 PRODUCT PROFILE SUMMARY: IXIARO/JESPECT</i> .....	33
Provenge.....	34
<i>TABLE 12 PRODUCT PROFILE SUMMARY: PROVENGE</i> .....	34
Provenge (Continued).....	35

Provenge (Continued) .....	36
DEVELOPMENT STAGE THERAPEUTIC VACCINES.....	36
MenB .....	37
<i>TABLE 13 PRODUCT PROFILE SUMMARY: MENB</i> .....	37
COMPANY ANALYSIS.....	38
OVERVIEW.....	38
GLAXOSMITHKLINE .....	38
Product and Pipeline Portfolio .....	38
<i>TABLE 14 PIPELINE SUMMARY: GSK</i> .....	38
Company Strategy .....	39
MERCK .....	40
Product and Pipeline Portfolio .....	40
<i>TABLE 15 PIPELINE SUMMARY: MERCK</i> .....	40
Company Strategy .....	41
NOVARTIS .....	42
Product and Pipeline Portfolio .....	42
<i>TABLE 16 PIPELINE SUMMARY: NOVARTIS</i> .....	42
Product and Pipeline ... (Continued) .....	43
Company Strategy .....	44
Company Strategy (Continued).....	45
PFIZER.....	46
Product and Pipeline Portfolio .....	46
<i>TABLE 17 PIPELINE SUMMARY: PFIZER</i> .....	46
Company Strategy .....	47
SANOFI-AVENTIS.....	48
Product and Pipeline Portfolio .....	49
<i>TABLE 18 PIPELINE SUMMARY: SANOFI-AVENTIS</i> .....	49
Company Strategy .....	50
Company Strategy (Continued).....	51
Company Strategy (Continued).....	52
CHAPTER FOUR: INFECTIOUS DISEASE TREATMENTS .....	53
INTRODUCTION .....	53
<i>TABLE 19 GLOBAL MARKET FOR INFECTIOUS DISEASE,</i> <i>THROUGH 2010 (\$ MILLIONS)</i> .....	54
PRODUCT SUMMARY AND MARKET .....	54
BACTERIAL DISEASE.....	54
Overview.....	54
<i>TABLE 20 CURRENT MARKET BY DRUG CLASS FOR BACTERIAL</i> <i>DISEASE, THROUGH 2010 (\$ MILLIONS)</i> .....	54
Cephalosporins .....	55
Penicillins.....	55
Fluoroquinolones .....	55
<i>TABLE 21 MARKET FOR LEADING PRODUCTS: BACTERIAL</i> <i>DISEASE, THROUGH 2010 (\$ MILLIONS)</i> .....	56

VIRAL INFECTIONS .....	57
<i>TABLE 22 MARKET BY DRUG CLASS FOR VIRAL INFECTION, THROUGH 2010 (\$ MILLIONS)</i> .....	57
AIDS/HIV .....	57
Nucleoside Reverse Transcriptase Inhibitor (NRTI) .....	58
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) .....	58
Protease Inhibitors .....	58
<i>TABLE 23 MARKET FOR LEADING PRODUCTS: VIRAL INFECTION DISEASE, THROUGH 2010 (\$ MILLIONS)</i> .....	59
VACCINES.....	59
<i>TABLE 24 MARKET BY DRUG CLASS FOR VACCINES, THROUGH 2010 (\$ MILLIONS)</i> .....	59
Hepatitis .....	60
Hepatitis A and E .....	60
Hepatitis B .....	60
Hepatitis C .....	60
Hepatitis C (Continued) .....	61
Hepatitis D (with B).....	62
Hepatitis G .....	62
Interferons.....	62
Antivirals.....	62
<i>TABLE 25 MARKET FOR LEADING PRODUCTS: VACCINE-TREATABLE DISEASE, THROUGH 2010 (\$ MILLIONS)</i> .....	63
FUNGAL INFECTIONS .....	63
<i>TABLE 26 MARKET BY DRUG CLASS FOR FUNGAL INFECTIONS, THROUGH 2010 (\$ MILLIONS)</i> .....	63
Fungal Infections (Continued) .....	64
<i>TABLE 27 MARKET FOR LEADING PRODUCTS: FUNGAL DISEASE, THROUGH 2010 (\$ MILLIONS)</i> .....	65
TRENDS AND INNOVATIONS IN INFECTIOUS DISEASE .....	65
KEY TRENDS IN INFECTIOUS DISEASE .....	65
Large and Growing Opportunity: Drug Resistant Infections .....	66
Emerging Markets Open HIV/AIDS Drugs to Fast Growth .....	66
Hepatitis C as Major Need Matched with Novel Last-Stage Compounds.....	66
Novel Vaccines Drive Future Sales Growth .....	66
Flu Pandemics Offer Latent Opportunity .....	67
MARKET FORECAST .....	67
<i>TABLE 28 MARKET FORECAST FOR INFECTIOUS DISEASE, THROUGH 2015 (\$ MILLIONS)</i> .....	68
PIPELINE ANALYSIS .....	68

<i>TABLE 29 PRODUCTS IN DEVELOPMENT BY STAGE AND INFECTIOUS DISEASE SEGMENT (NUMBER OF DEVELOPMENTAL PRODUCTS)</i> .....	69
PROFILES OF KEY PRODUCTS IN DEVELOPMENT .....	69
RECENTLY APPROVED DRUGS.....	69
Doribax.....	69
<i>TABLE 30 PRODUCT PROFILE SUMMARY: DORIBAX</i> .....	69
Isentress.....	70
<i>TABLE 31 PRODUCT PROFILE SUMMARY: ISENTRESS</i> .....	70
Prezista .....	71
<i>TABLE 32 PRODUCT PROFILE SUMMARY: PREZISTA</i> .....	71
Prezista (Continued) .....	72
Selzentry .....	73
<i>TABLE 33 PRODUCT PROFILE SUMMARY: SELZENTRY</i> .....	73
Eraxis .....	74
<i>TABLE 34 PRODUCT PROFILE SUMMARY: ERAXIS</i> .....	74
Gardasil.....	75
<i>TABLE 35 PRODUCT PROFILE SUMMARY: GARDASIL</i> .....	75
Ceftobiprole.....	76
<i>TABLE 36 PRODUCT PROFILE SUMMARY: CEFTOBIPROLE</i> .....	76
Cervarix .....	77
<i>TABLE 37 PRODUCT PROFILE SUMMARY: CERVARIX</i> .....	77
Cervarix (Continued) .....	78
Menveo .....	79
<i>TABLE 38 PRODUCT PROFILE SUMMARY: MENVEO</i> .....	79
PHASE III DEVELOPMENT STAGE DRUGS .....	80
Albupheron.....	80
<i>TABLE 39 PRODUCT PROFILE SUMMARY: ALBUFERON</i> .....	80
Tygacil.....	81
<i>TABLE 40 PRODUCT PROFILE SUMMARY: TYGACIL</i> .....	81
Tygacil (Continued).....	82
Numax.....	83
<i>TABLE 41 PRODUCT PROFILE SUMMARY: NUMAX</i> .....	83
Telaprevir.....	84
<i>TABLE 42 PRODUCT PROFILE SUMMARY: TELAPREVIR</i> .....	84
Vicriviroc .....	85
<i>TABLE 43 PRODUCT PROFILE SUMMARY: VICRIVIROC</i> .....	85
Pevnar 13vPnC .....	86
<i>TABLE 44 PRODUCT PROFILE SUMMARY: PREVNAR 13VPNC</i> .....	86
COMPANY ANALYSIS .....	87
ABBOTT .....	87
Company Overview.....	87
Products and Services .....	87
Company Strategy .....	88

BRISTOL-MYERS SQUIBB.....	88
Company Overview.....	88
Products and Services .....	89
Company Strategy .....	89
GILEAD SCIENCES.....	90
Company Overview.....	90
Products and Services .....	90
Company Strategy .....	91
GLAXOSMITHKLINE .....	91
Company Overview.....	91
Products and Services .....	92
Company Strategy .....	92
JOHNSON & JOHNSON .....	93
Company Overview.....	93
Products and Services .....	93
Company Strategy .....	94
MERCK .....	94
Company Overview.....	95
Products and Services .....	95
Company Strategy .....	96
NOVARTIS .....	96
Company Overview.....	96
Products and Services .....	97
Company Strategy .....	97
PFIZER .....	98
Company Overview.....	98
Products and Services .....	99
Company Strategy .....	99
SANOFI-AVENTIS.....	99
Company Overview.....	99
Products and Services .....	100
Company Strategy .....	100
Company Strategy (Continued).....	101
CHAPTER FIVE: BIOMARKERS.....	102
INTRODUCTION .....	102
<i>TABLE 45 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 (\$</i>	
<i>MILLIONS)</i> .....	103
ENABLING ADVANCEMENTS DRIVING MARKET GROWTH .....	103
BIOMARKERS DRIVE SPEED, COST AND QUALITY	
IMPROVEMENTS ACROSS THE DRUG DEVELOPMENT	
SPECTRUM .....	103
BIOMARKERS APPLICATIONS: DRUG DEVELOPMENT.....	104
Safety/Toxicology Biomarkers.....	105
Dose Selection and Dose Optimization .....	105

Improved Measurement of Therapeutic Efficacy .....	105
Outcome Biomarkers and Surrogate Endpoints .....	105
EARLY-STAGE CLINICAL TRIAL APPLICATIONS .....	106
LATE-STAGE CLINICAL TRIAL APPLICATIONS .....	107
Phase III.....	107
Phase IV.....	107
BIOMARKERS: CHALLENGES AND OPPORTUNITIES .....	107
SUMMARY .....	107
CLINICAL VALIDITY: REQUIREMENTS .....	108
BIOMARKER OPPORTUNITIES .....	108
PRODUCT SUMMARY AND MARKET.....	108
GENOMICS .....	108
<i>TABLE 46 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 (\$</i>	
<i>MILLIONS)</i> .....	<i>109</i>
IMAGING .....	109
PROTEOMICS.....	110
BIOINFORMATICS .....	110
OTHER .....	111
Metabonomics .....	111
BIOMARKER ADOPTION BY THE PHARMACEUTICAL	
INDUSTRY.....	111
GROWTH DRIVERS AND RESISTORS .....	111
FACTORS INFLUENCING BIOMARKER ADOPTION IN	
CLINICAL TRIALS .....	111
CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE....	112
IMPACT OF DRUG FAILURE IN LAST-STAGE CLINICAL	
TRIALS.....	112
Merck: Vicriviroc.....	112
ADDITIONAL CAPABILITIES BY LARGE SERVICE	
PLAYERS .....	113
TECHNOLOGICAL ADVANCEMENTS IN GENOMICS AND	
PROTEOMICS .....	113
BIOMARKER MARKET FORECAST.....	114
<i>TABLE 47 GLOBAL BIOMARKER MARKET FORECAST, THROUGH</i>	
<i>2015 (\$ MILLIONS)</i> .....	<i>114</i>
REGULATORY ENVIRONMENT .....	114
INTRODUCTION.....	114
ROLE OF THE FOOD AND DRUG ADMINISTRATION .....	114
<i>TABLE 48 FDA GUIDELINES FOR BIOMARKER APPLICATIONS .....</i>	<i>115</i>
EUROPEAN MEDICINES AGENCY .....	116
REGULATORY IMPACT ON DRUG SAFETY .....	117
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING .....	117
APPROVED PATENT ANALYSIS.....	117

<i>TABLE 49 ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS IN U.S., EUROPE, JAPAN, THROUGH 2010</i> .....	118
COMPETITIVE LANDSCAPE .....	118
LATE STAGE CLINICAL TRIALS: COMPETITIVE POSITIONING .....	118
<i>TABLE 50 GLOBAL MARKET FOR TOTAL CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2010 (\$ MILLIONS)</i> .....	119
<i>TABLE 51 GLOBAL MARKET FORECAST FOR CLINICAL STAGE BIOMARKERS, THROUGH 2015 (\$ MILLIONS)</i> .....	120
APPLICATION BY THERAPY AREA .....	120
<i>TABLE 52 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY</i> .....	120
<i>TABLE 52 (CONTINUED)</i> .....	121
<i>TABLE 53 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY THERAPEUTIC AREA, THROUGH 2010 (\$ MILLIONS)</i> .....	121
Oncology .....	121
<i>TABLE 54 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY</i> .....	122
Cardiovascular .....	122
<i>TABLE 55 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR</i> .....	123
Central Nervous System .....	123
<i>TABLE 56 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE</i> .....	124
Immunology .....	124
<i>TABLE 57 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY</i> .....	125
REPRESENTATIVE EXAMPLES WITHIN CANCER AND IMMUNOLOGY .....	125
Cancer .....	125
Elesclomol: Synta .....	125
Immunology .....	126
Benlysta: Human Genome Sciences .....	126
Cancer .....	126
Hereptin: Roche .....	126
Expedition and Identity .....	126
Alzheimer's Trial: Eli Lilly .....	126
LEADING COMPANIES .....	127
AFFYMETRIX, INC. .....	127
Company Overview .....	127
Products and Services .....	127
Company Strategy .....	127
BANYAN BIOMARKERS, INC. .....	128



Company Overview.....	128
Products and Services .....	128
Company Strategy .....	128
BG MEDICINE, INC.....	129
Company Overview.....	129
Products and Services .....	129
Company Strategy .....	129
BIOPHYSICAL CORP .....	130
Company Overview.....	130
Products and Services .....	130
Company Strategy .....	130
BIOSYSTEMS INTERNATIONAL INC .....	131
Company Overview.....	131
Products and Services .....	131
Company Strategy .....	131
CAPRION PROTEOMICS INC .....	132
Company Overview.....	132
Products and Services .....	132
Company Strategy .....	132
CLINICAL DATA, INC .....	133
Company Overview.....	133
Products and Services .....	133
Company Strategy .....	133
CORRELOGIC SYSTEMS, INC.....	134
Company Overview.....	134
Products and Services .....	134
Company Strategy .....	134
EPIGENOMICS AG .....	135
Company Overview.....	135
Products and Services .....	135
Company Strategy .....	135
GENEDATA AG .....	136
Company Overview.....	136
Products and Services .....	136
Company Strategy .....	137
GENEGO, INC. ....	137
Company Overview.....	137
Products and Services .....	137
Company Strategy .....	137
GENENEWS LTD .....	138
Company Overview.....	138
Products and Services .....	138
Company Strategy .....	139

SUMMARY.....	140
<i>TABLE 58 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE, THROUGH 2015 (\$ MILLIONS)</i> .....	141
EMERGING DRUG CLASSES .....	142
P2Y12 AND FACTOR XA INHIBITORS .....	142
<i>TABLE 59 CARDIOVASCULAR MARKET FORECAST BY DRUG CLASS, THROUGH 2015</i> .....	142
<i>TABLE 59 (CONTINUED)</i> .....	143
Effient (Prasugrel): a Leading P2Y12 Antagonist .....	143
<i>TABLE 60 P2Y12 MARKET GROWTH AND SHARE, THROUGH 2010 (\$ MILLIONS)</i> .....	144
<i>TABLE 61 PY12 MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i> .....	144
<i>TABLE 62 FACTOR XA CURRENT MARKET GROWTH AND SHARE (\$ MILLIONS)</i> .....	145
<i>TABLE 63 FACTOR XA MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i> .....	145
P2Y12 Inhibitors and Antagonists.....	145
Factor Xa Inhibitors .....	146
Cholesterol-Ester Transfer Protein (CETP) Inhibitor .....	146
<i>TABLE 64 CETP INHIBITORS IN ACTIVE DEVELOPMENT</i> .....	147
KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET.....	147
P2Y12 IS A PROVEN TARGET FOR MULTIPLE INDICATIONS; APPROVALS ARE EXPECTED. ....	147
PLAVIX METABOLIZER 2C19 TRIGGERS U.S. WARNING.....	147
VALTURNA FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR HYPERTENSION.....	148
VALTURNA FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR HYPERTENTION .....	149
ANTICOAGULANTS ENABLE NEW PRODUCT APPROVALS, IN PARTICULAR FACTOR XA .....	150
APOB-100 AS A NOVEL TREATMENT FOR HYPERLIPIDEMIA .....	151
INCREASED DRIVE TO ESTABLISH AND EXTEND HIGH HDL CHOLESTEROL LEVELS .....	151
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT .....	152
<i>TABLE 65 MARKET VALUE OF RECENTLY APPROVED DRUGS, 2009-2015 (\$ MILLIONS)</i> .....	153
<i>TABLE 66 SUMMARY PIPELINE FORECAST, 2009-2015 (\$ MILLIONS)</i> ....	153
INDUSTRY STRUCTURE .....	153
<i>TABLE 67 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH AND SHARE, THROUGH 2010 (\$ MILLIONS)</i> .....	154
MARKET TRENDS.....	155
Overall Market Flat: Higher Mix of Generics Offset by Higher Volume .....	155

<i>TABLE 68 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS, THROUGH 2015 (\$ MILLIONS)</i> .....	156
Massive Patent Expiration is a Growth Opportunity for Generics .....	156
Market Expansion via Disease Prevention is the Future of Cardio Care.....	157
Atrial Fibrillation is a Large and Emerging Disease State.....	157
Atrial Fibrillation ... (Continued) .....	158
Combination Therapies are Synergistic Revenue Generators .....	159
PIPELINE ANALYSIS .....	160
<i>TABLE 69 APPROVED PRODUCT FORECAST, 2010 AND 2015 (\$ MILLIONS)</i> .....	160
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT .....	160
2010 APPROVALS IN CARDIOVASCULAR THERAPY .....	161
MULTAQ (DRONEDARONE): SANOFI-AVENTIS.....	161
<i>TABLE 70 MULTAQ SNAPSHOT</i> .....	161
XARELTO (RIVAROXABAN): BAYER SCHERING/J&J.....	162
<i>TABLE 71 XARELTO SNAPSHOT</i> .....	163
EFFIENT/EFIENT (PRASUGREL): ELI LILLY/DAIICHI SANKYO .....	164
<i>TABLE 72 EFFIENT SNAPSHOT</i> .....	164
RENDIX (DABIGATRAN): BOEHRINGER INGELHEIM.....	165
<i>TABLE 73 RENDIX SNAPSHOT</i> .....	166
RECENTLY FILED/PRE-REGISTRATION COMPOUNDS .....	167
APIXABAN: BRISTOL-MYERS SQUIBB (BMS)/PFIZER.....	167
<i>TABLE 74 APIXABAN SNAPSHOT</i> .....	167
BRILINTA (TICAGRELOR/AZD6140): ASTRAZENECA.....	168
<i>TABLE 75 BRILINTA SNAPSHOT</i> .....	169
CERTRIAD (ROSUVASTATIN/ FENOFIBRIC ACID): ASTRAZENECA/ABBOTT .....	170
<i>TABLE 76 CERTRIAD SNAPSHOT</i> .....	170
PHASE II/III COMPOUNDS.....	171
LCZ696: NOVARTIS .....	171
<i>TABLE 77 LCZ696 SNAPSHOT</i> .....	171
EDOXABAN (DU-176B): DAIICHI SANKYO.....	172
<i>TABLE 78 EDOXABAN (DU-176B) SNAPSHOT</i> .....	172
SCH 530348 – MERCK .....	173
<i>TABLE 79 SCH530348 SNAPSHOT</i> .....	173
TYRISA/DARAPLADIB: GSK .....	174
<i>TABLE 80 TYRISA SNAPSHOT</i> .....	174
BETRIXABAN: PORTOLA/MERCK .....	175
<i>TABLE 81 BETRIXABAN SNAPSHOT</i> .....	176
PIPELINE ANALYSIS BY COMPANY .....	177

<i>TABLE 82 PFIZER'S CARDIOVASCULAR PIPELINE</i> .....	177
<i>TABLE 83 SANOFI-AVENTIS' CARDIOVASCULAR PIPELINE</i> .....	177
<i>TABLE 84 NOVARTIS' CARDIOVASCULAR PIPELINE</i> .....	177
<i>TABLE 85 MERCK'S CARDIOVASCULAR PIPELINE</i> .....	178
<i>TABLE 86 BMS' CARDIOVASCULAR PIPELINE</i> .....	178
<i>TABLE 87 ASTRA-ZENECA'S CARDIOVASCULAR PIPELINE</i> .....	178
COMPANY PROFILES .....	179
SUMMARY .....	179
<i>TABLE 88 COMPANY REVENUE AND MARKET SHARE ANALYSIS, THROUGH 2010 (\$ MILLIONS)</i> .....	179
<i>TABLE 89 MARKET FORECAST BY COMPANY, THROUGH 2015 (\$ MILLIONS)</i> .....	180
ASTRAZENECA .....	181
Business Overview .....	181
Leading Products .....	181
Crestor .....	181
Atacand .....	182
Certriad .....	182
Corporate Strategy .....	182
BRISTOL-MYERS SQUIBB COMPANY .....	183
Business Overview .....	183
Leading Products .....	183
Plavix .....	183
Apixaban .....	183
Corporate Strategy .....	183
MERCK & CO., INC. ....	184
Business Overview .....	184
Leading Products .....	184
Vytorin .....	184
Zetia .....	185
Cozaar .....	185
Hyzaar .....	186
Zocor .....	186
Corporate Strategy .....	186
PFIZER, INC. ....	187
Business Overview .....	187
Leading Products .....	187
Lipitor .....	187
Norvasc .....	188
Revatio .....	188
Corporate Strategy .....	188
SANOFI AVENTIS .....	189
Business Overview .....	189
Leading Products .....	189

Plavix.....	189
Lovenox .....	190
Multaq .....	190
Corporate Strategy .....	191
CHAPTER SEVEN: LEADING OPHTHALMIC TREATMENTS .....	192
<i>TABLE 90 GLOBAL OPHTHALMIC MARKET FORECAST BY DISEASE, THROUGH 2015 (\$ MILLIONS)</i> .....	192
LEADING OPHTHALMIC TREATMENTS (CONTINUED) .....	193
OVERVIEW.....	194
ESTABLISHED DRUG CLASSES IN OPHTHALMOLOGY.....	194
EMERGING DRUG CLASSES.....	194
VEGF-Trap Eye .....	194
Combination Therapies .....	194
COMPETITION BETWEEN VEGF INHIBITORS IN WET AMD....	195
<i>TABLE 91 NOTABLE EVENTS IN LUCENTIS VERSUS AVASTIN: PREVIOUS AND EXPECTED</i> .....	195
<i>TABLE 91 (CONTINUED)</i> .....	196
Expected Outcome of CATT Trial: Avastin v. Lucentis .....	196
PIPELINE ANALYSIS .....	197
<i>TABLE 92 APPROVED PRODUCT SALES FORECAST, 2008-2014 (\$ MILLIONS)</i> .....	197
<i>TABLE 93 PIPELINE SALES FORECAST, 2008-2014 (\$ MILLIONS)</i> .....	198
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT .....	198
STRINGENT REGULATORY PATHWAY EXISTS FOR DRY-EYE DISEASE .....	198
SUSTAINED DELIVERY IS A COMMON TRAIT AMONG LEADING PRODUCTS IN DEVELOPMENT.....	199
SIRNA THERAPIES IN DEVELOPMENT EXPERIENCE SYSTEMIC SAFETY CONCERNS .....	200
INDUSTRY STRUCTURE .....	201
MARKET CONCENTRATION AND PRICE SENSITIVITY.....	202
<i>TABLE 94 COMPANY BY DISEASE CLASS, 2009 REVENUE (\$ MILLIONS)</i> .....	203
COMPETITIVE FACTORS.....	203
<i>TABLE 95 LARGE-REVENUE BRANDED DRUG SALES COMING OFF-PATENT, 2009</i> .....	204
MARKET TRENDS.....	204
Demographics Offer Tremendous Long-run Opportunity .....	204
<i>TABLE 96 REVENUE GROWTH OF OPHTHALMOLOGY AS COMPARED TO TOTAL PHARMACEUTICAL MARKET, 2005-2010 (% YEAR-OVER-YEAR REVENUE GROWTH)</i> .....	205
An Increasingly Challenging Global Reimbursement Environment.....	205
Sustained Drug Delivery is the Future of Retinal Care .....	205

Payment Structures Important to Revenue Uptake and Peak Sales.....	206
Fundamental Patient Need: Blindness or Impaired Vision among the Most Debilitating Diseases.....	206
Combination Therapies Promise Improved Therapeutic Response.....	207
Expansion of Prescription Therapies to Rural Communities .....	207
<i>TABLE 97 NUMBER OF U.S. HOSPITALS PROVIDING OPHTHALMIC CARE (NUMBER/%).....</i>	<i>208</i>
<i>TABLE 98 NUMBER OF TRAINED, LICENSED, AND CERTIFIED OPHTHALMOLOGISTS .....</i>	<i>208</i>
<i>TABLE 99 REVENUE AND SHARE BY LEADING OPHTHALMIC PLAYERS, 2009 (\$ MILLIONS/%).....</i>	<i>208</i>
<i>TABLE 100 MARKET ANALYSIS BY DISEASE, 2008 AND 2009 (\$ MILLIONS/%).....</i>	<i>209</i>
<i>TABLE 101 LEADING OPHTHALMIC THERAPIES, TOTAL SEGMENT, 2009 (\$ MILLIONS/%).....</i>	<i>209</i>
NOTABLE MERGERS, ACQUISITIONS AND TRANSACTIONS.....	210
Roche/Genentech .....	210
Alcon/Novartis .....	210
Transaction Summary .....	210
Proposed Terms of Purchase .....	210
Proposed Terms ... (Continued).....	211
Integration Challenges and Opportunities.....	212
Fovea/Sanofi-Aventis.....	212
DETAILED PIPELINE REVIEW .....	213
2009 APPROVALS IN OPHTHALMOLOGY THERAPY.....	213
Acuvail .....	213
<i>TABLE 102 SNAPSHOT OF ACUVAIL.....</i>	<i>213</i>
Clinical Results .....	213
Bepreve .....	214
<i>TABLE 103 SNAPSHOT OF BEPREVE.....</i>	<i>214</i>
Clinical Results .....	214
Besivance .....	215
<i>TABLE 104 SNAPSHOT OF BESIVANCE .....</i>	<i>215</i>
Ozurdex.....	216
<i>TABLE 105 SNAPSHOT OF OZURDEX.....</i>	<i>216</i>
Ozurdex (Continued).....	217
Zirgan.....	218
OPHTHALMIC DRUGS IN ADVANCED DEVELOPMENT .....	218
PHASE III.....	218
VEGF Trap-Eye .....	218

<i>TABLE 106 SNAPSHOT OF VEGF TRAP-EYE</i> .....	219
Clinical Results .....	219
Iluvien .....	220
<i>TABLE 107 SNAPSHOT OF ILUVIEN</i> .....	220
Clinical Results .....	220
Luveniq .....	221
<i>TABLE 108 SNAPSHOT OF LUVENIQ</i> .....	221
PHASE II .....	222
Ecabet.....	222
<i>TABLE 109 SNAPSHOT OF ECABET</i> .....	222
Clinical Results .....	222
Androgen Tears .....	223
<i>TABLE 110 SNAPSHOT OF ANDROGEN TEARS</i> .....	223
PIPELINE ANALYSIS BY COMPANY .....	224
<i>TABLE 111 ALCON'S OPHTHALMIC PIPELINE</i> .....	224
<i>TABLE 112 ALLERGAN'S OPHTHALMIC PIPELINE</i> .....	224
<i>TABLE 113 PFIZER'S OPHTHALMIC PIPELINE</i> .....	225
<i>TABLE 114 NOVARTIS' OPHTHALMIC PIPELINE</i> .....	225
<i>TABLE 115 MERCK OPHTHALMIC PIPELINE</i> .....	225
<i>TABLE 116 SANTEN OPHTHALMIC PIPELINE</i> .....	225
COMPANY PROFILES .....	226
SUMMARY .....	226
ALCON .....	227
Business Overview .....	227
Leading Products .....	227
Pataday.....	227
Vigamox.....	227
Nevanac.....	228
Triesence .....	228
Tobradex.....	228
Travatan and Travatan Z .....	228
Azopt.....	228
Azarga .....	228
Duotrav.....	229
Corporate Strategy .....	229
ALLERGAN, INC. ....	229
Business Overview .....	229
Leading Products .....	229
Restasis and Others .....	229
Lumigan and Others.....	230
Corporate Strategy .....	230
GENENTECH/ROCHE .....	231
Business Overview .....	231
Leading Products .....	231

Lucentis .....	231
Avastin (Bevacizumab) .....	232
Corporate Strategy .....	232
INSPIRE PHARMACEUTICALS, INC .....	232
Business Overview .....	233
Leading Products .....	233
Prolacria (Diquafosol Tetrasodium) .....	233
Additional Products .....	233
Corporate Strategy .....	234
MERCK .....	234
Business Overview .....	234
Corporate Strategy .....	235
NOVARTIS .....	235
Business Overview .....	235
Leading Products .....	235
Lucentis .....	235
Visudyne .....	235
Company Strategy .....	236
OPKO HEALTH .....	236
Business Overview .....	236
Leading Products .....	236
Bevasiranib .....	236
Civamide .....	237
Doxovir .....	237
Company Strategy .....	237
PFIZER .....	238
Business Overview .....	238
Leading Products .....	238
Xalatan (Latanoprost Ophthalmic Solution) .....	238
Corporate Strategy .....	238
POTENTIA PHARMACEUTICALS .....	239
Business Overview .....	239
Leading Products .....	239
POT-4 .....	239
Corporate Strategy .....	239
QLT INC. ....	240
Business Overview .....	240
Leading Products .....	240
Visudyne .....	240
Corporate Strategy .....	240
REGENERON .....	241
Business Overview .....	241
Leading Products .....	241
VEGF-Trap Eye .....	241



Corporate Strategy .....	241
SANOFI-AVENTIS .....	242
Business Overview .....	242
Leading Products.....	242
Prednisporin.....	242
FOV2302.....	242
Corporate Strategy .....	243
SANTEN SEIYAKU .....	243
Business Overview .....	243
Leading Products.....	244
Hyalein .....	244
Cravit/Oftaquix .....	244
Corporate Strategy .....	244

## CHAPTER EIGHT: CNS: NEXT-GENERATION MECHANISMS OF

ACTION .....	245
<i>TABLE 117 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS, THROUGH 2015 (\$ MILLIONS)</i> .....	245
CNS: NEXT-GENERATION MECHANISMS ... CONTINUED) .....	246
KEY RECENT EVENTS IN THE CENTRAL NERVOUS SYSTEM MARKET.....	247
2009 FDA PEDIATRIC ADVISORY COMMITTEE ON PRESCRIPTION OF ANTIPSYCHOTICS .....	247
GROWTH SEEN VIA PURSUIT OF ADDITIONAL INDICATIONS VERSUS NCE APPROVALS .....	247
ALZHEIMER'S DRUGS IN JAPAN OPEN UP LARGE OPPORTUNITIES, DRIVEN BY DEMOGRAPHICS .....	248
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT .....	248
<i>TABLE 118 RECENTLY APPROVED AND PIPELINE FORECAST, 2009-2015 (\$ MILLIONS)</i> .....	248
MARKET TRENDS.....	249
OVERALL MARKET FLAT: HIGHER MIX OF GENERICS OFFSET BY HIGHER VOLUME.....	249
SIGNIFICANT IMPACT OF PATIENT ADVOCACY GROUPS IN CNS DISEASE.....	249
GROWTH SEEN VIA PURSUIT OF ADDITIONAL INDICATIONS VERSUS NCE APPROVALS .....	249
IMPROVING PERFORMANCE IN DEPRESSION TREATMENTS .....	250
ALZHEIMER'S THERAPY CONTINUES TO RECEIVE LARGE AND IMPORTANT INVESTMENT.....	250
<i>TABLE 119 PATENT EXPIRATION OF CENTRAL NERVOUS SYSTEM DRUGS, 2010 AND 2015 (\$ MILLIONS)</i> .....	251
<i>TABLE 120 MARKET SHARE BY LEADING CENTRAL NERVOUS SYSTEM PLAYERS, 2010 (\$ MILLIONS/%)</i> .....	251

TABLE 120 (CONTINUED).....	252
TABLE 121 LARGEST REVENUE GENERATING THERAPIES IN THE CENTRAL NERVOUS SYSTEM DISEASE, THROUGH 2010 (\$ MILLIONS).....	252
CHAPTER NINE: MARKETS BY DISEASE .....	253
SUMMARY OF MARKET DYNAMICS .....	253
TABLE 122 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS, THROUGH 2015 (\$ MILLIONS).....	254
PSYCHIATRY .....	254
MARKET DYNAMICS .....	254
Market Dynamics (Continued).....	255
TABLE 123 GLOBAL PSYCHIATRY MARKET, THROUGH 2015 (\$ MILLIONS).....	255
TABLE 123 (CONTINUED).....	256
DEPRESSION .....	256
Market Dynamics .....	256
TABLE 124 GLOBAL DEPRESSION MARKET, THROUGH 2015 (\$ MILLIONS).....	257
Generic Drug Trends: Depression.....	257
TABLE 125 GLOBAL DEPRESSION MARKET, THROUGH 2015 (\$ MILLIONS).....	257
TABLE 125 (CONTINUED).....	258
MULTIPLE SCLEROSIS AND PARKINSON'S.....	258
MARKET DYNAMICS .....	258
TABLE 126 GLOBAL MS AND PARKINSON'S MARKET THROUGH 2010 (\$ MILLIONS).....	259
GENERIC DRUG TRENDS: PARKINSON'S .....	259
TABLE 127 GLOBAL MS AND PARKINSON'S MARKET, THROUGH 2015 (\$ MILLIONS).....	260
EPILEPSY/CONVULSIONS .....	260
MARKET DYNAMICS .....	260
TABLE 128 GLOBAL EPILEPSY MARKET, THROUGH 2010 (\$ MILLIONS).....	261
TABLE 129 GLOBAL EPILEPSY MARKET, THROUGH 2015 (\$ MILLIONS).....	261
GENERIC DRUG TRENDS: EPILEPSY/CONVULSIONS .....	262
ALZHEIMER'S.....	262
MARKET DYNAMICS .....	262
TABLE 130 GLOBAL ALZHEIMER'S MARKET, THROUGH 2010 (\$ MILLIONS).....	263
TABLE 131 GLOBAL ALZHEIMER'S MARKET, THROUGH 2015 (\$ MILLIONS).....	263
TABLE 131 (CONTINUED).....	264
GENERIC DRUG TRENDS: ALZHEIMER'S .....	264

ADHD AND NARCOLEPSY .....	264
MARKET DYNAMICS .....	264
<i>TABLE 132 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2010</i> (\$ MILLIONS).....	265
<i>TABLE 133 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2015</i> (\$ MILLIONS).....	265
GENERIC DRUG TRENDS: ADHD/NARCOLEPSY .....	266
MIGRAINE AND OTHER CNS DISEASE.....	266
MARKET DYNAMICS .....	266
<i>TABLE 134 GLOBAL MIGRAINE MARKET, THROUGH 2015 (\$</i> <i>MILLIONS)</i> .....	266
<i>TABLE 135 GLOBAL OTHER CENTRAL NERVOUS SYSTEM</i> <i>MARKET, THROUGH 2015 (\$ MILLIONS)</i> .....	267
PIPELINE ANALYSIS .....	267
<i>TABLE 136 APPROVED PRODUCT FORECAST, 2009-2015 (\$</i> <i>MILLIONS)</i> .....	268
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT .....	268
KEY TRENDS IN RESEARCH AND DEVELOPMENT.....	268
SNRIs Improve the Baseline Performance of Leading Depression Therapies.....	268
New Products Provide Larger Opportunities Compared to Product Extensions .....	269
Combination Products Yield Greater Therapeutic Response .....	269
Alzheimer's Therapy Continues to Receive Large and Important Investment.....	269
KEY PRODUCTS UNDER MAJOR CNS DISORDERS .....	270
Schizophrenia .....	270
Depression.....	270
Alzheimer's .....	271
Parkinson's Disease.....	272
Epilepsy.....	272
Insomnia .....	272
Attention Deficit Hyperactivity Disorder .....	272
Other Indications.....	273
2009 APPROVALS IN CENTRAL NERVOUS SYSTEM THERAPY.....	273
PHASE III AND PENDING APPROVAL COMPOUNDS.....	273
<i>TABLE 137 BAPINEUZUMAB (AAB-001): ELAN/WYETH/PFIZER</i> .....	273
Phase III and Pending ... (Continued).....	274
<i>TABLE 138 TELCAGEPANT (MK-0974): MERCK</i> .....	275
Phase III and Pending ... (Continued).....	276
<i>TABLE 139 SOLANEZUMAB (LY2062430): ELI LILLY</i> .....	277
<i>TABLE 140 SEMAGACESTAT (LY450139): ELI LILLY</i> .....	278
<i>TABLE 141 VILAZODONE: CLINICAL DATA</i> .....	279

RECENTLY APPROVED/MARKETED DRUGS.....	280
<i>TABLE 142 STEDESA/ZEBINIX (ESLICARBAZEPINE ACETATE):</i>	
<i>DAINIPPON SUMITOMO (FORMERLY SEPRACOR)</i> .....	280
<i>TABLE 143 INTUNIV (GUANFACINE): SHIRE</i> .....	281
<i>TABLE 144 TREXIMET (SUMATRIPTAN AND NAPROXEN):</i>	
<i>GSK/POZEN</i> .....	282
<i>TABLE 145 PRISTIQ (DESVENLAFAXINE): PFIZER/WYETH</i> .....	283
Recently Approved/... (Continued).....	284
<i>TABLE 146 VIMPAT (LACOSAMIDE): UCB/SCHWARZ PHARMA</i> .....	285
<i>TABLE 147 DEVELOPMENTAL PRODUCT FORECAST 2009-2015 (\$</i>	
<i>MILLIONS)</i> .....	286
 CHAPTER TEN: COMPANY PROFILES .....	287
SUMMARY.....	287
COMPANIES .....	287
ABBOTT LABORATORIES .....	287
Business Overview .....	287
Therapeutic Areas.....	288
<i>TABLE 148 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	288
Corporate Strategy .....	288
ALLERGAN, INC. ....	288
Business Overview .....	288
Therapeutic Areas.....	289
<i>TABLE 149 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	289
Corporate Strategy .....	289
ASTELLAS PHARMA, INC. ....	289
Business Overview .....	289
Therapeutic Areas.....	289
<i>TABLE 150 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	290
Corporate Strategy .....	290
ASTRAZENECA .....	290
Business Overview .....	290
Therapeutic Areas.....	291
<i>TABLE 151 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	291
Corporate Strategy .....	291
BAYER AG .....	292
Business Overview .....	292
Therapeutic Areas.....	292
<i>TABLE 152 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	293
Corporate Strategy .....	293

BIOGEN IDEC (FUMAPHARM AG) .....	293
Business Overview .....	293
Therapeutic Areas.....	293
<i>TABLE 153 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	<i>294</i>
Corporate Strategy .....	294
ELI LILLY & CO. ....	294
Business Overview .....	294
Therapeutic Areas.....	294
<i>TABLE 154 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	<i>295</i>
Corporate Strategy .....	295
FOREST LABORATORIES, INC. ....	295
Business Overview .....	296
Therapeutic Areas.....	296
<i>TABLE 155 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	<i>296</i>
Corporate Strategy .....	296
GLAXOSMITHKLINE (GSK) .....	297
Business Overview .....	297
Therapeutic Areas.....	297
<i>TABLE 156 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	<i>297</i>
Corporate Strategy .....	297
JOHNSON & JOHNSON.....	298
Business Overview .....	298
Therapeutic Areas.....	298
<i>TABLE 157 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	<i>298</i>
Corporate Strategy .....	299
MERCK & CO., INC.....	299
Business Overview .....	299
Therapeutic Areas.....	300
<i>TABLE 158 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	<i>300</i>
Corporate Strategy .....	300
NOVARTIS AG (NOVARTIS PHARMACEUTICALS).....	300
Business Overview .....	300
Therapeutic Areas.....	301
<i>TABLE 159 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	<i>301</i>
Corporate Strategy .....	301
PFIZER, INC. ....	301
Business Overview .....	302

Therapeutic Areas.....	302
<i>TABLE 160 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	302
Corporate Strategy .....	302
SANOFI-AVENTIS .....	303
Business Overview .....	303
Therapeutic Areas.....	303
<i>TABLE 161 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	304
Corporate Strategy .....	304
SHIRE PHARMACEUTICALS GROUP, PLC.....	304
Business Overview .....	304
Therapeutic Areas.....	304
<i>TABLE 162 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	305
Corporate Strategy .....	305
Business Overview .....	305
Therapeutic Areas.....	306
<i>TABLE 163 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	306
Corporate Strategy .....	306
TEVA PHARMACEUTICAL INDUSTRIES LTD.....	306
Business Overview .....	306
Therapeutic Areas.....	307
<i>TABLE 164 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	307
Corporate Strategy .....	307
WATSON PHARMACEUTICALS, INC. ....	307
Business Overview .....	308
Therapeutic Areas.....	308
<i>TABLE 165 LEADING PRODUCTS AND REVENUE, 2009 (\$</i>	
<i>MILLIONS)</i> .....	308
Corporate Strategy .....	308
CHAPTER ELEVEN: CANCER TRENDS: EVOLVING THERAPIES .....	309
INTRODUCTION .....	309
TRENDS IN ONCOLOGY DRUG DEVELOPMENT.....	309
PERSONLIZED TREATMENTS BECOMING STANDARD OF	
CARE.....	309
VACCINES IMPROVE ACCESS TO IMMUNE RESPONSE.....	310
COST TO SERVE IS NEXT FRONTIER OF	
DIFFERENTIATION.....	310
ONCOLOGISTS REPLACE DRUG COMPANIES TO DELIVER	
COMBINATION THERAPY.....	311

<i>TABLE 166 ONCOLOGY MARKETS BY TYPE OF THERAPY, THROUGH 2010 (\$ MILLIONS)</i> .....	311
MARKET ANALYSIS BY DRUG CLASS .....	311
KEY RECENT EVENTS IN THE CANCER MARKET .....	312
FDA WITHDRAWS BREAST CANCER INDICATION FOR AVASTIN.....	312
MYLOTARG WITHDRAWN BASED ON BOTH SAFETY AND EFFICACY CONCERNS .....	312
JEVTANA APPROVED FOR METASTATIC HORMONE-REFRACTORY PROSTATE CANCER .....	313
STIMUVAX PHASE III TRIALS RESUMED BY MERCK SERONO .....	313
FDA CONTINUES GARDASIL REVIEW.....	314
NEOPLASIA THERAPY .....	314
COMPETITIVE DYNAMICS OF NEOPLASIA THERAPY.....	314
<i>TABLE 167 ONCOLOGY MARKETS BY DRUG CLASS, THROUGH 2010 (\$ MILLIONS)</i> .....	315
LEADING NEOPLASIA THERAPY BRANDS .....	316
TOTAL NEOPLASIA THERAPY MARKET .....	316
<i>TABLE 168 ONCOLOGY MARKETS BY LARGEST THERAPEUTIC DRUGS, THROUGH 2010 (\$ MILLIONS)</i> .....	316
NEOPLASIA THERAPY MAB MARKET ANALYSIS .....	317
MARKET DYNAMICS .....	317
PRODUCT REVIEW .....	317
Erbix (Cetuximab).....	317
Nexavar (Sorafenib).....	318
NEOPLASIA THERAPY PROTEIN KINASE INHIBITORS .....	319
MARKET DYNAMICS .....	319
PRODUCT REVIEW .....	319
VINCA ALKALOID MARKET ANALYSIS.....	319
MARKET DYNAMICS .....	319
PRODUCT REVIEW .....	320
ANTI-METABOLITES .....	320
MARKET DYNAMICS .....	320
PRODUCT REVIEW .....	320
PLATINUM COMPOUNDS.....	320
MARKET DYNAMICS .....	320
PRODUCT REVIEW .....	321
NEOPLASIA THERAPY SALES FORECAST .....	321
<i>TABLE 169 NEOPLASIA MARKET FORECAST BY LEADING PRODUCTS, THROUGH 2015 (\$ MILLIONS)</i> .....	322
HORMONAL THERAPIES .....	322
COMPETITIVE DYNAMICS OF HORMONAL THERAPIES .....	322

<i>TABLE 170 HORMONAL THERAPIES MARKETS, THROUGH 2010 (\$ MILLIONS)</i> .....	323
LEADING HORMONAL THERAPY PRODUCTS .....	323
<i>TABLE 171 LEADING PRODUCTS IN HORMONAL THERAPIES SEGMENT, THROUGH 2010 (\$ MILLIONS)</i> .....	324
CYTOSTATIC AROMATASE INHIBITORS MARKET ANALYSIS.....	324
MARKET DYNAMICS .....	324
PRODUCT REVIEW .....	324
Arimidex (Anastrozole): AstraZeneca .....	324
Femara (Letrozole): Novartis .....	325
CYTOSTATIC GONADOTROPHIN-RELEASING HORMONE ANALOG MARKET ANALYSIS .....	325
MARKET DYNAMICS .....	325
PRODUCT REVIEW .....	326
CYTOSTATIC ANTI-ANDROGENS .....	326
MARKET DYNAMICS .....	326
PRODUCT REVIEW .....	327
Casodex (Bicalutamide): AstraZeneca .....	327
HORMONAL THERAPY SALES FORECAST.....	327
<i>TABLE 172 FORECAST FOR HORMONAL THERAPIES BY LEADING PRODUCTS, THROUGH 2015 (\$ MILLIONS)</i> .....	328
GLOBAL CANCER MARKET SALES FORECAST .....	328
<i>TABLE 173 ONCOLOGY MARKET FORECAST BY TYPE OF THERAPY, THROUGH 2015 (\$ MILLIONS)</i> .....	328
PIPELINE ANALYSIS .....	329
Recently Approved/Marketed Drugs .....	329
Afinitor (Everolimus): Novartis .....	329
<i>TABLE 174 PIPELINE DRUG SNAPSHOT: AFINITOR</i> .....	329
Arzerra (Ofatumumab): GSK/Genmab .....	330
<i>TABLE 175 PIPELINE DRUG SNAPSHOT: ARZERRA</i> .....	330
Arzerra (Ofatumumab): (Continued).....	331
Votrient (Pazopanib): GSK.....	332
<i>TABLE 176 PIPELINE DRUG SNAPSHOT: VOTRIENT</i> .....	332
Votrient (Pazopanib): ... (Continued).....	333
Provence (Sipuleucel-T): Dendreon .....	334
<i>TABLE 177 PIPELINE DRUG SNAPSHOT: PROVENGE</i> .....	334
Trastuzumab-DM1 (T-DM1): Roche.....	335
<i>TABLE 178 PIPELINE DRUG SNAPSHOT: TRASTUZUMAB</i> .....	335
<i>TABLE 179 RECENT (ROCHE-SPONSORED) CLINICAL TRIALS INVOLVING HERCEPTIN-DM1 COMPOUND (TRASTUZUMAB)</i> .....	336
PHASE III COMPOUNDS .....	337
Stimuvax (Emepepimut- S): Merck Serono .....	337
<i>TABLE 180 PIPELINE DRUG SNAPSHOT: STIMUVAX</i> .....	337
Ipilimumab (MDX-010): Bristol Myers Squibb (BMS) .....	338



<i>TABLE 181 PIPELINE DRUG SNAPSHOT: IPILIMUMAB</i> .....	338
<i>TABLE 182 RECENT CLINICAL TRIALS INVOLVING IPILIMUMAB</i> .....	339
Omnitarg (Pertuzumab): Roche .....	340
<i>TABLE 183 PIPELINE DRUG SNAPSHOT: OMNITARG</i> .....	340
<i>TABLE 184 RECENT CLINICAL TRIALS INVOLVING OMNITARG</i> .....	340
<i>TABLE 184 (CONTINUED)</i> .....	341
Abiraterone: Johnson & Johnson (J&J).....	341
<i>TABLE 185 PIPELINE DRUG SNAPSHOT: ABIRATERONE</i> .....	341
<i>TABLE 186 RECENT CLINICAL TRIALS INVOLVING ABIRATERONE</i> .....	342
BSI-201 (Iniparib): Sanofi-Aventis .....	342
<i>TABLE 187 PIPELINE DRUG SNAPSHOT: INIPARIB</i> .....	342
BSI-201 (Iniparib): ...ontinued).....	343
<i>TABLE 188 FORECAST OF LEADING DRUGS IN DEVELOPMENT,</i> <i>THROUGH 2015 (\$ MILLIONS)</i> .....	344
COMPANY ANALYSIS .....	344
<i>TABLE 189 MARKET BY LEADING PLAYERS IN ONCOLOGY,</i> <i>THROUGH 2010 (\$ MILLIONS)</i> .....	344
ROCHE .....	345
Company Summary .....	345
Drug Class Focus .....	345
Product and Pipeline Portfolio .....	345
<i>TABLE 190 2010 ROCHE TOP PRODUCTS SALES (\$ MILLIONS)</i> .....	346
NOVARTIS .....	347
Company Summary .....	347
Drug Class Focus .....	347
Product and Pipeline Portfolio .....	348
<i>TABLE 191 NOVARTIS TOP PRODUCTS SALES, THROUGH 2010 (\$</i> <i>MILLIONS)</i> .....	348
SANOFI-AVENTIS.....	349
Company Summary .....	349
Drug Class Focus .....	349
<i>TABLE 192 SANOFI-AVENTIS TOP PRODUCTS SALES, THROUGH</i> <i>2010 (\$ MILLIONS)</i> .....	350
Product and Pipeline Portfolio .....	350
ASTRAZENECA .....	351
Company Summary .....	351
Drug Class Focus .....	351
Product and Pipeline Portfolio .....	351
<i>TABLE 193 ASTRA-ZENECA TOP PRODUCTS SALES, THROUGH</i> <i>2010 (\$ MILLIONS)</i> .....	352
ELI LILLY & CO. ....	352
Company Summary .....	353
Drug Class Focus .....	353
Product and Pipeline Portfolio .....	353

*TABLE 194 ELI LILLY TOP PRODUCTS SALES, THROUGH 2010 (\$ MILLIONS)..... 354*